Bayer logo
US MEDICAL AFFAIRS
Contact Us icon

Publications

Publications

Home / Publications 

We invite you to explore Bayer-supported publications. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

To help narrow down your search, choose the relevant tags and click Apply. Selecting multiple tags will narrow your results.

Last updated March 2025.

IPPI: Immediate Postpartum Insertion

SD: Sleep Disturbances

PK: Pharmacokinetics

IUD: Intrauterine Device

VMS: Vasomotor Symptoms

Types of Enhancements Available

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 29    

Filtered results: 29

Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer

Cardoso F, et al. N Engl J Med. 2025. Online ahead of print.

Cardoso F., Parke S., Brennan D.J., Briggs P., Donders G., Panay,
READ
EMAIL

Psychometric evaluation of the HFDD, PROMIS SD SF 8b, and MENQOL questionnaire in women experiencing vasomotor symptoms associated with menopause

Trigg A, et al. J Patient Rep Outcomes. 2025; 9(1):50.

Trigg A, Barclay M, Whyman S, Lehane A, Bradley H, Gerlinger C,,
READ
EMAIL

Real-world use of antispasmodic drugs during IUD insertion - insights from the large observational study EURAS-LCS12

Eggebrechet, L, et al. Contracept Reprod Health Care. 2025. Online ahead of print.

Eggebrecht L, Rizzo M, Klinghardt M, Böhnke T, Barnett C, and He,
READ
EMAIL

Population characteristics of intrauterine device users in real-world clinical practice across Europe - insights from the EURAS-LCS12 study

Eggebrecht L, Bauerfeind A, Boehnke T, Rizzo M, Hagemann C, Lange J, Viet M, Pauls K, von Stockum S, Klinghardt M, Heinemann K. Contracept Reprod Med.

Eggebrecht L., Bauerfeind A. Boehnke T., Rizzo M., Hagemann C., ,
READ
EMAIL

Consensus recommendations for measuring the impact of contraception on the menstrual cycle in contraceptive clinical trials

Mackenzie ACL, et al. Contraception. Jan 2025; Online ahead of print.

Mackenzie A.C.L., Chung S., Hoppes E., Miller N., Burke A.E., Ac,
READ
EMAIL

Population pharmacokinetic-pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data

Willmann S, et al. CPT Pharmacometrics Syst Pharmacol. July 2024;00:1-13.

Willmann S, Lloyd A, Austin R, Joseph S, Solms A, Zhang Y, Schne,
READ
EMAIL

Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials

Pinkerton J, et al. JAMA. Aug 2024; Online Ahead of Print.

Pinkerton J,
READ
EMAIL

Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: Findings from the REALISE study.

Kingsberg S, et al. Maturitas. Aug 2024; 22(189):108096.

Kingsberg A,
READ
EMAIL

Assessing Contraceptive Switching and Discontinuation Over 3 Years in the HER Salt Lake Study

Simmons RG. Obstet Gynecol. Jul 2024; 144(1):79-88.

Simmons R. G., Carter G., Sanders J. N., Turok D. K.,
READ
EMAIL

Treatment utilization and non-drug interventions for vasomotor symptoms in breast cancer survivors taking endocrine therapy: Real-world findings from the United States and Europe

Kingsberg S, et al. Maturitas. 2024 Jul; 23:188:108071.

Kingsberg S,
READ
EMAIL
Bayer logo

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

 

© 2025 Bayer. Bayer and the Bayer Cross are registered trademarks for Bayer.

Site last updated 05/2025